Anavex Life Sciences Corp.(AVXL)今日盘前大涨7.33%,引发市场关注。从相关新闻来看,该公司最新阿尔茨海默病候选药物blarcamesine获得了重大进展,推动了股价上涨。
该公司新发布的第三季度财报显示,虽然亏损持续扩大,但营收表现符合预期。更令投资者振奋的是,该公司阿尔茨海默病新药blarcamesine已获欧盟监管机构接受上市申请。一旦获批上市,blarcamesine将成为口服治疗阿尔茨海默病的新选择,填补了现有注射类药物的空白。
另外,blarcamesine无需进行核磁共振等额外检测,且具有独特的作用机制,可作为现有抗体药物的补充或替代方案,潜在应用前景广阔。再加上公司现金储备充足,可维持约4年的运营,为新药上市销售奠定了坚实基础。综合利好因素,市场对Anavex的长期发展前景充满信心,推动股价今日盘前大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.